Curis (NASDAQ:CRIS) Stock Rating Reaffirmed by HC Wainwright

Curis (NASDAQ:CRIS)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a note issued to investors on Friday, Benzinga reports. They currently have a $26.00 price target on the biotechnology company’s stock. HC Wainwright’s target price points to a potential upside of 412.82% from the company’s previous close.

Curis Stock Performance

CRIS stock opened at $5.07 on Friday. The company’s 50 day moving average price is $5.36 and its 200 day moving average price is $9.17. The firm has a market capitalization of $29.88 million, a price-to-earnings ratio of -0.59 and a beta of 3.33. Curis has a fifty-two week low of $3.80 and a fifty-two week high of $17.49.

Curis (NASDAQ:CRIS) last announced its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($2.03) EPS for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.36). The firm had revenue of $2.55 million during the quarter, compared to analysts’ expectations of $2.20 million. Curis had a negative net margin of 468.18% and a negative return on equity of 327.92%. During the same period in the prior year, the company posted ($2.40) earnings per share. Equities analysts forecast that Curis will post -6.79 EPS for the current fiscal year.

Institutional Trading of Curis

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in shares of Curis by 4.8% in the 1st quarter. Vanguard Group Inc. now owns 218,573 shares of the biotechnology company’s stock valued at $2,376,000 after acquiring an additional 10,097 shares during the last quarter. Franklin Street Advisors Inc. NC purchased a new position in Curis in the first quarter valued at approximately $219,000. Point72 Asset Management L.P. raised its holdings in Curis by 795.5% during the second quarter. Point72 Asset Management L.P. now owns 108,356 shares of the biotechnology company’s stock worth $748,000 after purchasing an additional 96,256 shares in the last quarter. CM Management LLC lifted its position in shares of Curis by 380.0% during the 1st quarter. CM Management LLC now owns 120,000 shares of the biotechnology company’s stock worth $1,304,000 after buying an additional 95,000 shares during the last quarter. Finally, Focused Wealth Management Inc boosted its holdings in shares of Curis by 79.2% in the 1st quarter. Focused Wealth Management Inc now owns 33,158 shares of the biotechnology company’s stock valued at $360,000 after buying an additional 14,656 shares in the last quarter. 29.97% of the stock is owned by hedge funds and other institutional investors.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.